Transthyretin Amyloidosis Treatment Market, By Drug (Inostersen, Partisiran, Tafamidis, and Others), By Indication (Wild Type ATTR Amyloidosis, and Hereditary ATTR Amyloidosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Market Trends, Analysis, and Forecast till 2029

Report Code: PMI458620 | Publish Date: May 2023 | No. of Pages: 149

Global Transthyretin Amyloidosis Treatment Market Overview

Transthyretin amyloidosis may be a rare progressive fatal disease that destroys the nerve cells controlling various bodily functions. The symptoms of the disease are almost like those of the many other diseases. Moreover, patients affected by the condition die ten years after the onset of symptoms. Therefore, timely symptom identification, diagnosis, and treatment are important. Transthyretin amyloidosis is caused due to the misfolding of the transthyretin (TTR) protein, which may be a secondary transporter of thyroxine and retinol-binding protein. The misfolding causes protein depositions referred to as amyloids to make within tissues and organs. There are three types of transthyretin amyloidosis. In familial amyloid polyneuropathy (TTR-FAP) amyloids cause damage of the nerves that control the senses, movement, and involuntary bodily functions. The second type is transthyretin amyloidosis cardiomyopathy (TTR-CM) that results in cardiomyopathy. It causes damage to the heart’s muscles, inhibiting the power to pump blood throughout the body. The third type is senile systemic amyloidosis (SSA), which is more prevalent in men than women. The global transthyretin amyloidosis treatment market accounted for US$ 40.5 million in 2019 and is anticipated to register a CAGR of 58.7%.

Impact of Covid-19 pandemic on market

With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). This report will quantify the impact of a pandemic on the transthyretin amyloidosis treatment market.

Global Transthyretin Amyloidosis Treatment Market Dynamics

Increasing prevalence of transthyretin amyloidosis

The global transthyretin amyloidosis treatment market is likely to be driven by an increase in the prevalence of disease, rise in the population with African origin, increase in awareness, improvement in diagnostic procedures, improving health care services, rapid economic growth in developing countries, and rise in research and development activity. For instance, According to the Amyloidosis Foundation, there are roughly 126 different genetic variations in ATTR, with up to 53 types of genetic variations in non-transthyretin hereditary amyloidosis diseases. According to reports published on transthyretin amyloidosis, it has been estimated that nearly 10,000, or 1.1 per 100,000 individuals in the world are living with TTR-FAP. The age group of patients suffering from the disorder is between 30 and 40 years of age. It has also been observed that TTR-CM tends to affect older males aged 65 years and above. Familial amyloid polyneuropathy (TTR-FAP) leads to 100 different types of mutations in the transthyretin gene, which leads to protein misfolding. There is only a 50% chance of transferring the mutation to the next generation from an affected parent. On the other hand, the mutation that leads to familial amyloid cardiomyopathy is generally found in individuals of African origin. Amyloidosis related to age primarily affects Caucasian men who are aged 65 years and above.

Increasing healthcare awareness among people

The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, and incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Transthyretin Amyloidosis Treatment Market Segmentation

 

The global transthyretin amyloidosis treatment market is segmented based on drug, indication, distribution channel, and region.

On the basis of drug, the global transthyretin amyloidosis treatment market is segmented into inostersen, partisiran, tafamidis, and others. Based on indication, the target market is segmented into wild type ATTR amyloidosis, and hereditary ATTR amyloidosis. Based on distribution channel, the target market is segmented into retail pharmacy, hospital pharmacy, and online pharmacy.

Regional Insights:

On region the global transthyretin amyloidosis treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North Americas dominates the market for Transthyretin (TTR) amyloidosis owing to the increasing prevalence of amyloidosis among adults and older population and rising geriatric population which is a major trigger factor for this disease. For instance, according to a report published by ASCO Journal in 2016 around 4,000 people developed amyloidosis each year in the United States. Thus, this rising patient pool is going to boost up the market growth during the forecast period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising use of technologically advanced medical diagnostic devices are likely to drive the market. The presence of pharmaceutical giants such as Pfizer, Merck, etc. also propels the market growth in this region.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2029

Market representation

Revenue in USD Million & CAGR from 2020 – 2029

Market Segmentation

By Drug: Inostersen, Partisiran, Tafamidis, and Others

By Indication: Wild Type ATTR Amyloidosis, and Hereditary ATTR Amyloidosis

By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy

Delivery Mode Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the global transthyretin amyloidosis treatment market report based on drug, indication, distribution channel, and region.

Global Transthyretin Amyloidosis Treatment Market, By Drug:

  • Inostersen
  • Partisiran
  • Tafamidis
  • Others

Global Transthyretin Amyloidosis Treatment Market, By Indication:

  • Wild Type ATTR Amyloidosis
  • Hereditary ATTR Amyloidosis

Global Transthyretin Amyloidosis Treatment Market, By Distribution Channel:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

Global Transthyretin Amyloidosis Treatment Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Transthyretin Amyloidosis Treatment Market Key Players

The key players operating in the global transthyretin amyloidosis treatment market includes Prothena Corporation plc., Pfizer Inc., Ionis Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Celgene Corporation, Takeda Pharmaceutical Company Ltd., Johnson and Johnson Pvt. Ltd., GlaxoSmithKline plc, Alnylam Pharmaceuticals Inc., SOM Innovation Biotech S.L., AstraZeneca plc. The market is especially characterized by collaborations and partnerships between the businesses and acquisitions of smaller players as a part of strategic expansion as well as launching their new product specimen. For instance, In August 2018, Alnylam Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for its ONPATTRO (patisiran) lipid complex injection— a RNA interference (RNAi) therapeutic— indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Global Transthyretin Amyloidosis Treatment Market Company Profile

  • Prothena Corporation plc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer Inc.
  • Ionis Pharmaceuticals Inc.
  • Valeant Pharmaceuticals International Inc.
  • Celgene Corporation
  • Takeda Pharmaceutical Company Ltd.
  • Johnson and Johnson Pvt. Ltd.
  • GlaxoSmithKline plc
  • Alnylam Pharmaceuticals Inc.
  • SOM Innovation Biotech S.L.
  • AstraZeneca plc.

Global Transthyretin Amyloidosis Treatment Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Transthyretin Amyloidosis Treatment Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Drug
      • Market Snippet, By Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Transthyretin Amyloidosis Treatment Market, By Drug, 2019 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
      • Y-o-Y Growth Analysis (%), 2019 – 2029
      • Segment Trends
    • Inostersen
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
    • Partisiran
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
    • Tafamidis
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
  6. Global Transthyretin Amyloidosis Treatment Market, By Indication, 2019 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
      • Y-o-Y Growth Analysis (%), 2019 – 2029
      • Segment Trends
    • Wild Type ATTR Amyloidosis
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
    • Hereditary ATTR Amyloidosis
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
  7. Global Transthyretin Amyloidosis Treatment Market, By Distribution Channel, 2019 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
      • Y-o-Y Growth Analysis (%), 2019 – 2029
      • Segment Trends
    • Retail Pharmacy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
    • Hospital Pharmacy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
    • Online Pharmacy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
  8. Global Transthyretin Amyloidosis Treatment Market, By Region, 2019 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
      • Y-o-Y Growth Analysis (%), 2019 – 2029
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Drug, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Indication, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Drug, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Indication, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Drug, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Indication, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Drug, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Indication, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Drug, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Indication, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2019 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  10. Company Profiles
      • Prothena Corporation plc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Business Strategies
      • Pfizer Inc.
      • Ionis Pharmaceuticals Inc.
      • Valeant Pharmaceuticals International Inc.
      • Celgene Corporation
      • Takeda Pharmaceutical Company Ltd.
      • Johnson and Johnson Pvt. Ltd.
      • GlaxoSmithKline plc
      • Alnylam Pharmaceuticals Inc.
      • SOM Innovation Biotech S.L.
      • AstraZeneca plc.
  11. The Last Word
    • Future Impact
    • About Us
    • Contact

List of Tables

TABLE List of data sources

TABLE Market drivers; Impact Analysis

TABLE Market restraints; Impact Analysis

TABLE Transthyretin Amyloidosis Treatment Market: Drug Snapshot (2019)

TABLE Segment Dashboard; Definition and Scope, by Drug

TABLE Global Transthyretin Amyloidosis Treatment Market, by Drug 2019-2029 (USD Million)

TABLE Transthyretin Amyloidosis Treatment Market: Indication Snapshot (2019)

TABLE Segment Dashboard; Definition and Scope, by Indication

TABLE Global Transthyretin Amyloidosis Treatment Market, by Indication 2019-2029 (USD Million)

TABLE Transthyretin Amyloidosis Treatment Market: Distribution Channel Snapshot (2019)

TABLE Segment Dashboard; Definition and Scope, by Distribution Channel

TABLE Global Transthyretin Amyloidosis Treatment Market, by Distribution Channel 2019-2029 (USD Million)

TABLE Transthyretin Amyloidosis Treatment Market: Regional snapshot (2019)

TABLE Segment Dashboard; Definition and Scope, by Region

TABLE Global Transthyretin Amyloidosis Treatment Market, by Region 2019-2029 (USD Million)

TABLE North America Transthyretin Amyloidosis Treatment Market, by Country, 2019-2029 (USD Million)

TABLE North America Transthyretin Amyloidosis Treatment Market, by Drug, 2019-2029 (USD Million)

TABLE North America Transthyretin Amyloidosis Treatment Market, by Indication, 2019-2029 (USD Million)

TABLE North America Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2019-2029 (USD Million)

TABLE Europe Transthyretin Amyloidosis Treatment Market, by Country, 2019-2029 (USD Million)

TABLE Europe Transthyretin Amyloidosis Treatment Market, by Drug, 2019-2029 (USD Million)

TABLE Europe Transthyretin Amyloidosis Treatment Market, by Indication, 2019-2029 (USD Million)

TABLE Europe Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2019-2029 (USD Million)

TABLE Asia Pacific Transthyretin Amyloidosis Treatment Market, by Country, 2019-2029 (USD Million)

TABLE Asia Pacific Transthyretin Amyloidosis Treatment Market, by Drug, 2019-2029 (USD Million)

TABLE Asia Pacific Transthyretin Amyloidosis Treatment Market, by Indication, 2019-2029 (USD Million)

TABLE Asia Pacific Transthyretin Amyloidosis Treatment Market, by Distribution channel, 2019-2029 (USD Million)

TABLE Latin America Transthyretin Amyloidosis Treatment Market, by Country, 2019-2029 (USD Million)

TABLE Latin America Transthyretin Amyloidosis Treatment Market, by Drug, 2019-2029 (USD Million)

TABLE Latin America Transthyretin Amyloidosis Treatment Market, by Indication, 2019-2029 (USD Million)

TABLE Latin America Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2019-2029 (USD Million)

TABLE Middle East and Africa Transthyretin Amyloidosis Treatment Market, by Country, 2019-2029 (USD Million)

TABLE Middle East and Africa Transthyretin Amyloidosis Treatment Market, by Drug, 2019-2029 (USD Million)

TABLE Middle East and Africa Transthyretin Amyloidosis Treatment Market, by Indication, 2019-2029 (USD Million)

TABLE Middle East and Africa Transthyretin Amyloidosis Treatment Market, by Distribution Channel, 2019-2029 (USD Million)

List of Figures

FIGURE Transthyretin Amyloidosis Treatment Market segmentation

FIGURE Market research methodology

FIGURE Value chain analysis

FIGURE Porter’s Five Forces Analysis

FIGURE Market Attractiveness Analysis

FIGURE COVID-19 Impact Analysis

FIGURE Pre & Post COVID-19 Impact Comparison Study

FIGURE Competitive Landscape; Key company market share analysis, 2019

FIGURE Drug segment market share analysis, 2019 & 2029

FIGURE Drug segment market size forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Indication segment market share analysis, 2019 & 2029

FIGURE Indication segment market size forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Distribution Channel segment market share analysis, 2019 & 2029

FIGURE Distribution Channel segment market size forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Regional segment market share analysis, 2019 & 2029

FIGURE Regional segment market size forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE North America Transthyretin Amyloidosis Treatment Market share and leading players, 2019

FIGURE Europe Transthyretin Amyloidosis Treatment Market share and leading players, 2019

FIGURE Asia Pacific Transthyretin Amyloidosis Treatment Market share and leading players, 2019

FIGURE Latin America Transthyretin Amyloidosis Treatment Market share and leading players, 2019

FIGURE Middle East and Africa Transthyretin Amyloidosis Treatment Market share and leading players, 2019

FIGURE North America market share analysis by country, 2019

FIGURE U.S. Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Canada Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Europe Transthyretin Amyloidosis Treatment Market share analysis by country, 2019

FIGURE Germany Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Spain Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Italy Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE UK Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE France Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Rest of the Europe Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Asia Pacific Transthyretin Amyloidosis Treatment Market share analysis by country, 2019

FIGURE India Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE China Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Japan Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE South Korea Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Rest of APAC Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Latin America Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Latin America Transthyretin Amyloidosis Treatment Market share analysis by country, 2019

FIGURE Brazil Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Mexico Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Argentina Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Rest of LATAM Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Middle East and Africa Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Middle East and Africa Transthyretin Amyloidosis Treatment Market share analysis by country, 2019

FIGURE Saudi Arabia Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE United Arab Emirates Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)

FIGURE Rest of Middle East and Africa Transthyretin Amyloidosis Treatment Market size, forecast and trend analysis, 2019 to 2029 (USD Million)